Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab and Epacadostat for Extensive Stage Small Cell Lung Cancer
NCT03402880Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- Oct 2018
- Primary completion
- Oct 2018
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, epacadostat in small cell lung cancer (SCLC), sponsored by City of Hope. Planned start Oct 2018; status: withdrawn.
02
Drugs
pembrolizumabepacadostat
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT03402880.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03402880.